Plaintiffs flee WDTX; Why Intel’s NPE move makes sense; IP strategy at NuCurrent; Message from new IAM editor; Campinos’ legacy challenge at the EPO; plus much more
Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week
Access all areas
With the latest news, analysis and data from the global IP market, an IAM subscription enables you to make effective decisions and advise with confidence. To learn more about how to secure full, unlimited access to the platform, contact [email protected]
MONDAY 15 August
The hub-and-spokes model provides new means of developing and monetising deprioritised or unwanted patent-backed innovations in the life sciences sector. Read more here
Although IPValue holds thousands of patents and has been active for over 20 years, Docket Navigator data shows that the firm’s entities have filed just 32 litigation actions since 2008. Read more here
TUESDAY 16 August
In an exclusive interview, Biocon Biologics’ chief IP counsel explains the issues that he and his team focus on – and how an upcoming, big-ticket merger will lead to change. Read more here
Following a lull in US biosimilar patent litigation in recent years, a new wave of originator versus biologic disputes has begun. Read more here
NuCurrent’s CEO Jacob Babcock details the company’s journey to becoming a technology licensing business and the philosophy that sustains it. Read more here
WEDNESDAY 17 August
Demonstrating ROI in patent operations is a challenge for many corporate IP functions. It’s one the team at Pure Storage understands and has made a central part of its overall strategy. Read more here
Mysterious patent-purchasing biotech company Terran Biosciences is embroiled in a US trade secrets dispute with competitor Compass Pathways. Read more here
There’s been a significant decline in new patent cases in the Western District of Texas since filings began being randomly assigned to 12 judges instead of Alan Albright alone. Read more here
THURSDAY 18 August
Although it is tempting to think that obtaining patents for AI-related inventions is too difficult to try, there are ways through to getting meaningful protection from the EPO. Read more here
António Campinos was recently appointed to a second term as president of the EPO and now has until the end of June 2028 to leave an indelible mark on Europe’s patent story. Read more here
Nestlé and Coca-Cola have been named the world's most valuable food and beverage brands, as the industry finally shows signs of bouncing back from the covid-19 pandemic. Read more here
FRIDAY 19 August
Patent invalidation actions won’t derail litigation disputes in China but can prove an important bargaining chip when negotiating SEP licensing deals. Read more here
IAM is pleased to announce the release of IAM Life Sciences: Key issues for senior life sciences executives 2022. Read more here
Intel coined the term “patent troll” and has been highly critical of NPEs, but negative business headwinds mean that putting a portfolio of IP assets to work with IPValue is a no brainer. Read more here
SATURDAY 20 August
New IAM editor Rachel Mountain sets out her vision for the platform’s future at a time when interest in IP as a business asset has never been greater. Read more here
